Found 49 matching trials
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
PHASE3This is a randomised, multicentre, controlled, open-label, Phase III global...
Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases
EARLY_PHASE1This is an open clinical pharmacological translational Research Study, aimi...
Location
The Third the People's Hospital of Bengbu
The BCMA/CD19 Dual Targeted CAR-T Cell in Participants With Autoimmune Kidney Diseases
PHASE1This study is a single-center, open-label, dose-escalation exploratory clin...
Anti-BCMA or/and Anti-CD19 CART Cells Treatment of Relapsed Multiple Myeloma
PHASE1This phase I trial studies the side effects and best dose of BCMA CART cell...
Location
Shenzhen Second People's Hospital,The first affiliated hospital of Shenzhen University
Sequential CAR-T Cells Targeting BCMA/CD19 in Patients With Relapsed/ Refractory Autoimmune Diseases
PHASE1This is an open, single-arm, clinical study to evaluate the efficacy and sa...
Location
District One Hospital
Restoration of Immunity to Vaccine Preventable Diseases After CART-T Cell Therapy
N/AThe goal of this observational study is to learn about vaccine immunity in ...
Location
University Hospital Bern
Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
PHASE1Phase 1/2 umbrella study evaluates biomarker-selected dual-target CAR-T cel...
Location
Peking University Shenzhen Hospital
Targeting CD19 and BCMA CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Multiple Myeloma
PHASE1Evaluation the safety,tolerability, preliminary efficacy,and PK/PD of KQ-20...
Location
Hematology Department of ShanXi Cancer Hospital
A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory Multiple Myeloma
PHASE1This is a multicenter, open-label, dose-escalation/expansion phase 1/2a stu...
Location
Chinese Academy of Medical Sciences & Peking Union Medical College Hospital
Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Acute B Lymphocytic Leukemia
PHASE1Evaluation the safety,tolerability, preliminary efficacy,and PK/PD of CD19-...
Location
Hematology Department of ShanXi Cancer Hospital